The clinical study is being directed by Steffen Weikert, assistant director of the clinic for Urology at the Charite of Berlin.
The primary goal of this study is to investigate the safety and tolerability of the medication.
In addition effectiveness data is recorded, which contain the clinical, immunological and radiological parameters of the patients.
Mologen has also achieved a decisive milestone in an additional product segment with the start of the clinical study for the renal cancer medication MGN1601.
Mologen Clinical Development Department director Marina Tschaika said with MGN1601 they hope to have developed a cancer therapy with few side effects, which will lead to long-term relief of cancer suffering and, at the same time, to a clear improvement in the quality of life for patients with advanced renal cancer.
The procedures developed by Mologen for cell-based gene therapy against renal cancer involve a therapeutic vaccination to combat advanced tumors of the kidneys and the prevention of their reappearance after operations and medical treatment.